[HTML][HTML] Interferons and multiple sclerosis: Lessons from 25 years of clinical and real-world experience with intramuscular interferon beta-1a (Avonex)
SL Cohan, BA Hendin, AT Reder, K Smoot, R Avila… - CNS drugs, 2021 - Springer
Abstract Recombinant interferon (IFN) β-1b was approved by the US Food and Drug
Administration as the first disease-modifying therapy (DMT) for multiple sclerosis (MS) in …
Administration as the first disease-modifying therapy (DMT) for multiple sclerosis (MS) in …
Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients
T Sejbaek, HH Nielsen, N Penner, T Plavina… - Journal of Neurology …, 2019 - jnnp.bmj.com
Objectives In a prospective phase IV trial of the first-line oral treatment dimethyl fumarate
(DMF), we examined dynamics of neurofilament light (NFL) chain in serum, plasma and …
(DMF), we examined dynamics of neurofilament light (NFL) chain in serum, plasma and …
Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis
EJ Baughman, JP Mendoza, SB Ortega, CL Ayers… - Journal of …, 2011 - Elsevier
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous
system (CNS). MS is thought to be T-cell-mediated, with prior research predominantly …
system (CNS). MS is thought to be T-cell-mediated, with prior research predominantly …
Immune regulatory CNS-reactive CD8+ T cells in experimental autoimmune encephalomyelitis
NR York, JP Mendoza, SB Ortega, A Benagh… - Journal of …, 2010 - Elsevier
Immune-based self-recognition and failure to modulate this response are believed to
contribute to the debilitating autoimmune pathology observed in multiple sclerosis (MS) …
contribute to the debilitating autoimmune pathology observed in multiple sclerosis (MS) …
[HTML][HTML] Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in …
D Ontaneda, J Nicholas, M Carraro, J Zhou… - Multiple sclerosis and …, 2019 - Elsevier
Background Previous real-world comparative research of MS disease modifying therapies
(DMTs) in the overall population has suggested dimethyl fumarate (DMF) to be comparable …
(DMTs) in the overall population has suggested dimethyl fumarate (DMF) to be comparable …
[HTML][HTML] Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase 3 EVOLVE-MS-1 study
S Wray, F Then Bergh, A Wundes, DL Arnold… - Advances in …, 2022 - Springer
Introduction Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis
(MS) with the same active metabolite as dimethyl fumarate (DMF). DRF has a safety/efficacy …
(MS) with the same active metabolite as dimethyl fumarate (DMF). DRF has a safety/efficacy …
[HTML][HTML] Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter …
SL Cohan, H Moses, J Calkwood, C Tornatore… - Multiple sclerosis and …, 2018 - Elsevier
Background Delayed-release dimethyl fumarate (DMF) may be a therapeutic option for
patients with relapsing-remitting multiple sclerosis (RRMS) who are treated with natalizumab …
patients with relapsing-remitting multiple sclerosis (RRMS) who are treated with natalizumab …
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity
EE Longbrake, Y Mao-Draayer… - Multiple Sclerosis …, 2021 - journals.sagepub.com
Background: Delayed-release dimethyl fumarate (DMF) demonstrates sustained efficacy
and safety for relapsing forms of MS. Absolute lymphocyte count (ALC) is reduced initially …
and safety for relapsing forms of MS. Absolute lymphocyte count (ALC) is reduced initially …
The disease-ameliorating function of autoregulatory CD8 T cells is mediated by targeting of encephalitogenic CD4 T cells in experimental autoimmune …
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the CNS, and CD8
T cells are the predominant T cell population in MS lesions. Given that transfer of CNS …
T cells are the predominant T cell population in MS lesions. Given that transfer of CNS …
Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer …
K Kresa-Reahl, P Repovic, D Robertson… - Clinical …, 2018 - Elsevier
Purpose The goal of this study was to evaluate clinical outcomes and patient-reported
outcomes (PROs) over 12 months in patients with relapsing multiple sclerosis (RMS) who …
outcomes (PROs) over 12 months in patients with relapsing multiple sclerosis (RMS) who …